Log In
Print
BCIQ
Print
Print this Print this
 

AGS-16M8F

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionAntibody-drug conjugate (ADC) targeting phosphodiesterase-I beta (ENPP3; NPP3; CD203c)
Molecular Target Phosphodiesterase-I beta (ENPP3) (NPP3) (CD203c)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationRenal cancer
Indication DetailsTreat metastatic renal cancer
Regulatory Designation

Partner

Seattle Genetics Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today